Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses

Abstract

Background

Magnetic resonance imaging (MRI) of lesions in the brain may be the best current candidate for a surrogate biological marker of clinical outcomes in relapsing remitting multiple sclerosis (MS), based on its role as an objective indicator of disease pathology. No biological surrogate marker has yet been validated for MS clinical outcomes.

Objective

The objective of this study was to use a multi-phased study to determine if a valid surrogate relationship could be demonstrated between counts of contrast enhancing lesions (CELs) and occurrence of relapses in MS.

Methods

We examined correlations for the concurrent and predictive relationship between CELs over 6 months and MS relapses over the same 6 months and an additional 6 months (total: 12 months), using available data on untreated patients from a large clinical trial and natural history database.

Results

Concurrent and predictive correlations were inadequate to justify continuation of this study to the planned additional phases required to demonstrate a surrogate relationship between CELs and MS relapses.

Conclusions

Confidence intervals for correlations between CELs and MS relapses exclude the possibility that CELs can be a good surrogate for relapses over the time scales we investigated. Further exploration of surrogacy between MRI measures and MS clinical outcomes may require improved datasets, the development of MRI techniques that couple better to clinical disease, and the ability to test a wide range of imaging- and clinically-based hypotheses for surrogacy.

Keywords

multiple sclerosis magnetic resonance imaging gadolinium enhanced lesions surrogacy prognosis correlations

Get full access to this article

View all access options for this article.

References

1 IFNB Multiple Sclerosis Study Group . Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. 1. Clinical results from a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655 – 661 .

2 Johnson KP Brooks BR Cohen JA Ford CC Goldstein J Lisak RP . Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results from a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995; 45: 1268 – 1276 .

3 Jacobs LD Cookfair DL Rudick RA Herndon RM Richert JR Salazar AM . Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285 – 294 .

4 PRISMS . (Prevention of Relapses and Disability by Interferon-beta 1a Subsequently in Multiple Sclerosis) Study Group. Randomized, double-blind, placebo-controlled study of interferon-beta 1a in relapsing-remitting multiple sclerosis: clinical results. Lancet 1998; 352: 1498 – 1504 .

5 Hartung HP Gonsette R König N Kwiecinski H Guseo A Morrissey SP . Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomized, multicentre trial. Lancet 2002; 360: 2018 – 2025 .

6 Polman CH O’Connor PW Havrdova E Hutchinson M Kappos L Miller DH . A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899 - 910 .

7 Whitaker JN McFarland HF Rudge P Reingold SC . Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Mult Scler 1995; 1: 37 – 47 .

8 McFarland HF Barkhof F Antel J Miller DH . The role of MRI as a surrogate outcome measure in multiple sclerosis. Mult Scler 2002; 8: 40 – 51 .

9 McFarland HF Reingold SC . The future of multiple sclerosis therapies: redesigning multiple sclerosis clinical trials in a new therapeutic era. Mult Scler 2005; 11: 669 – 676 .

10.

10 Fleming TR . Surrogate endpoints and the FDA’s accelerated approval process. Health Aff 2005; 24: 67 – 78 .

11.

11 Miller DH Grossman RI Reingold SC McFarland HF . The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 1998; 121: 3 – 24 .

12.

12 Miller DH Khan OA Sheremata WA Blumhardt LD Rice GP Libonati MA . A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 115 – 123 .

13.

13 Fleming TR Demets RL . Surrogate endpoints in clinical trials: are we being misled? Ann Intern Med 1996; 125: 605 – 613 .

14.

14 Prentice RL . Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989; 8: 431 – 440 .

15.

16.

16 Ioannidis JPA . Why most published research findings are false. PLoS Med 2005; 2: e124

17.

17 Young PJ Lederer C Eder K Daumer M Neiss A Polman CH . Relapses and subsequent worsening of disability in relapsing remitting multiple sclerosis. Neurology 2005; 67: 804 – 808 .

18.

18 Lehmann EL . Nonparametrics: statistical methods based on ranks. San Francisco : Holden-Day, Inc. , 1975.

19.

19 Schach S Scholz M Wolinsky JS Kappos L . Pooled historical MRI data as a basis for research in multiple sclerosis – A statistical evaluation. Mult Scler 2007; 13: 509 – 516 .

20.

20 Comi G Filippi M Wolinsky JS . European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001; 49: 290 – 297 .

21.

21 Molyneux PD Barker GJ Barkhof F Beckmann K Dahlke F Filippi M . Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS. Neurology 2001; 57: 2191 – 2197 .

22.

22 Sormani MP Bruzzi P Beckmann K Wagner K Miller DH Kappos L . MRI metrics as surrogate endpoints for EDSS progression in SPSM patients treated with IFN beta-1b. Neurology 2003; 60: 1462 – 1466 .

23.

23 Kappos L Moeri D Radue EW Schoetzau A Schweikert K Barkhof F . Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet 1999; 353: 964 – 969 .

24.

24 Agosta F Rovaris M Pagani E Sormani MP Comi G Filippi M . Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis. Brain 2006; 129: 2620 – 2627 .

25.

25 Held U Heigenhauser L Shang C Kappos L Polman C . Predictors of relapse rate in MS clinical trials. Neurology 2005; 65: 1769 – 1773 .